The Bristol-based biotech start-up has closed its pre-seed round ahead of commercial production and launch.
"There is so much biological information that could enable early intervention for healthcare, but no route to clear access. The menstrual cycle is a non-invasive route to giving our users better health data for better health outcomes,. Many health conditions are difficult for researchers to analyse at the moment because they require invasive testing or regular monitoring which is inconvenient, time-intensive and often uncomfortable. Emm has the potential to do this in a practical, painless way."
The financing round was backed by Maven Capital Partners, YFM Equity Partners, Triple Point Ventures, and regional funds to support US growth.
"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."
The funding round was led by Archangels to support market entry for the company screening technology.
"Hearing loss usually advances slowly and unnoticeably and has severe consequences if left unmanaged. Our mission is to make reliable hearing testing accessible outside of specialist clinics to drive the early diagnosis of hearing loss and to ensure positive patient outcomes."
The Exeter-based HR technology firm secured backing from Mercia alongside existing investor Qantx to drive platform development and international expansion.
"We are delighted to be backing another South West company, and one that promotes diversity and inclusion. RoleMapper offers a unique range of services, some of which would previously have been carried out by large consulting firms at substantial cost. It has rapidly gained traction and attracted an impressive blue-chip client list. The investment will help it to establish itself as a ‘must have’ tool to help organisations navigate the future of work."
